Senores Pharmaceuticals (NSE:SENORES) First Quarter 2026 Results
Key Financial Results
- Revenue: ₹1.41b (up 38% from 1Q 2025).
- Net income: ₹197.3m (up 24% from 1Q 2025).
- Profit margin: 14% (down from 16% in 1Q 2025). The decrease in margin was driven by higher expenses.
- EPS: ₹4.60.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Senores Pharmaceuticals Earnings Insights
Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's shares are up 9.1% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Senores Pharmaceuticals' balance sheet.
Valuation is complex, but we're here to simplify it.
Discover if Senores Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.